Home > Riviste > Journal of Neurosurgical Sciences > Fascicoli precedenti > Journal of Neurosurgical Sciences 2020 October;64(5) > Journal of Neurosurgical Sciences 2020 October;64(5):434-9

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

ORIGINAL ARTICLE   

Journal of Neurosurgical Sciences 2020 October;64(5):434-9

DOI: 10.23736/S0390-5616.17.04209-6

Copyright © 2017 EDIZIONI MINERVA MEDICA

lingua: Inglese

Determination of the cutoff point of the absolute value of MGMTmRNA for predicting the therapeutic resistance to temozolomide in glioblastoma

Satoshi TANAKA 1 , Jiro AKIMOTO 2, Yoshitaka NARITA 3

1 Department of Neuro-Oncology and Neurosurgery, Tokyo Nishi Tokushukai Hospital, Akishima, Japan; 2 Department of Neurosurgery, Tokyo Medical University Hospital, Tokyo, Japan; 3 Division of Neurosurgery, National Cancer Center Hospital, Tokyo, Japan



BACKGROUND: We previously reported that the absolute value of O6-methylguanine-DNA methyltransferase (MGMT) messenger RNA (mRNA) obtained using real-time reverse transcription polymerase chain reaction (RT-PCR) might be useful for predicting both the prognosis and the results of therapy for glioblastoma (GB) treated by temozolomide (TMZ).
METHODS: MGMT mRNA was measured in 55 newly diagnosed cases of GB less than 75 and had a Karnofsky performance status (KPS) of at least 60 by real-time reverse transcription polymerase chain reaction (RT-PCR) using the TaqMan probe. A receiver operating characteristic analysis was performed to determine the cutoff points for progression free survival (PFS) and overall survival (OS).
RESULTS: In 55 patients with GB, 1200 and 3600 for PFS, 1200, 2100 and 2900 copies/μgRNA for OS were the candidate cutoff points. Significantly longer PFS and OS were observed in patients who did not exceed 1200 copies/μg RNA.
CONCLUSIONS: One thousand and two hundred copies/μg RNA appeared to be the most reasonable cutoff point of MGMTmRNA in GB for deciding to use other anti-tumor drugs such as Bevacizumab together with TMZ.


KEY WORDS: Glioblastoma; Reverse transcriptase polymerase chain reaction; Temozolomide

inizio pagina